NCT05813860View on ClinicalTrials.gov

HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

976

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

October 31, 2026

Conditions

Crohn DiseaseInfliximab

Interventions

DRUG

Azathioprine

azathioprine in combination with Infliximab, with a dose of 1-2 mg/kg/d.

DRUG

Infliximab

5mg/kg for the first dose, and the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter. Treatment with single Infliximab or combined azathioprine, respectively.

All Listed Sponsors

lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER

NCT05813860 - HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease | Biotech Hunter | Biotech Hunter